• LAST PRICE
    0.0290
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0290/ 100
  • Ask / Lots
    0.0359/ 200
  • Open / Previous Close
    --- / 0.0290
  • Day Range
    ---
  • 52 Week Range
    Low 0.0170
    High 0.0450
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.0275
TimeVolumeOTLC
09:32 ET100000.029
09:39 ET644900.0252
09:51 ET200000.024
10:27 ET50000.02575
10:29 ET10000.02575
10:33 ET5000.026
11:02 ET1149900.02725
11:03 ET870000.027
11:05 ET200000.02705
11:18 ET30000.028
11:23 ET500000.027
11:59 ET230000.0279
12:01 ET590000.0285
12:03 ET200000.0293
12:24 ET50000.02915
12:26 ET220000.02921
12:44 ET575000.02915
12:46 ET250000.02915
12:48 ET400000.029225
12:50 ET800000.02915
12:57 ET500000.03
01:02 ET200000.0306
01:15 ET200000.03
01:18 ET561410.03
01:20 ET100000.02908
01:29 ET1300000.029
01:51 ET5000.0295
03:30 ET127280.03
03:57 ET1381710.029
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOTLC
Oncotelic Therapeutics Inc
11.8M
-9.4x
---
United StatesKZIA
Kazia Therapeutics Ltd
18.1M
-0.7x
---
United StatesIMNN
Imunon Inc
11.8M
-0.4x
---
United StatesBIOR
Biora Therapeutics Inc
11.5M
0.0x
---
United StatesINDP
Indaptus Therapeutics Inc
12.1M
-0.6x
---
United StatesTXTM
Protext Mobility Inc
12.3M
0.0x
---
As of 2024-11-08

Company Information

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.

Contact Information

Headquarters
29397 Agoura Road Suite 107AGOURA HILLS, CA, United States 91301
Phone
650-635-7000
Fax
650-635-7001

Executives

Chairman of the Board, Chief Executive Officer
Vuong Trieu
Chief Financial Officer
Amit Shah
Chief Medical Officer - Translation Medicine
Anthony Maida
Chief Medical Officer, Chief Regulatory Officer (Consultant)
Seymour Fein
Chief Business Officer
Saran Saund

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.8M
Revenue (TTM)
$70.0K
Shares Outstanding
406.3M
Oncotelic Therapeutics Inc does not pay a dividend.
Beta
-0.27
EPS
$0.00
Book Value
$0.03
P/E Ratio
-9.4x
Price/Sales (TTM)
168.3
Price/Cash Flow (TTM)
---
Operating Margin
-1,177.41%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.